Literature DB >> 6613429

[Features of the clinical manifestation of contusion of the cerebral hemisphere in patients with hypertension].

A P Romodanov, E G Pedachenko.   

Abstract

Analysis of 401 cases with contusion of the cerebral hemispheres showed that in patients with craniocerebral trauma and essential hypertension the incidence of traumatic intracranial hematoma was 1.3-1.4 times higher and the incidence of acute cerebral circulatory disorders (mainly cerebral infarctions) was 4-5 times higher. Isolated contusion of the cerebral hemispheres in patients with essential hypertension was characterized by less manifested symptoms of internal hypertension and the dislocation syndrome. The combination of craniocerebral injury and essential hypertension has a marked effect on the clinical manifestations of both the craniocerebral trauma and essential hypertension.

Entities:  

Mesh:

Year:  1983        PMID: 6613429

Source DB:  PubMed          Journal:  Zh Vopr Neirokhir Im N N Burdenko        ISSN: 0042-8817


  3 in total

1.  Prognostic properties of the association between the S-100B protein levels and the mean cerebral blood flow velocity in patients diagnosed with severe traumatic brain injury.

Authors:  Sebastian Dzierzęcki; Mirosław Ząbek; Artur Zaczyński; Ryszard Tomasiuk
Journal:  Biomed Rep       Date:  2022-05-19

2.  Usability of the Level of the S100B Protein, the Gosling Pulsatility Index, and the Jugular Venous Oxygen Saturation for the Prediction of Mortality and Morbidity in Patients with Severe Traumatic Brain Injury.

Authors:  Ryszard Tomasiuk; Sebastian Dzierzęcki; Artur Zaczyński; Mirosław Ząbek
Journal:  Biomed Res Int       Date:  2021-10-25       Impact factor: 3.411

3.  The S-100B level, intracranial pressure, body temperature, and transcranial blood flow velocities predict the outcome of the treatment of severe brain injury.

Authors:  Sebastian Dzierzęcki; Mirosław Ząbek; Gabriela Zapolska; Ryszard Tomasiuk
Journal:  Medicine (Baltimore)       Date:  2022-09-23       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.